Strona 1 od 26 wyniki
FIELD OF THE INVENTION
The present invention relates to (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol
FIELD OF THE INVENTION
The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2011/066343, filed Sep. 20, 2011, which claims priority from European Patent Application No. 10178315.7, filed Sep. 22, 2010 and European Patent Application No. 11157858.9, filed Mar. 11,
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2012/053455, filed Feb. 29, 2012, which claims priority from European Patent Application No. 11156463.9, filed Mar. 1, 2011, the entire disclosures of which are hereby incorporated in their
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase application, under 35 U.S.C. 371, of international application No. PCT/KR2009/007898, filed on Dec. 29, 2009, which claimed priority to Korean Patent Application No. 10-2008-0135519, filed on Dec. 29, 2008, the disclosures
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2012/053863 filed Mar. 7, 2012, which claims priority from European Patent Application No. 11157418.2, filed Mar. 9, 2011, the entire disclosures of which are hereby incorporated in their
FIELD OF THE INVENTION
The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions
CROSS REFERENCE TO RELATED APPLICARIONS
This application is the national stage of PCT Application No. PCT/EP2014/062283, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171723.3,filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2014/062285, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171730.8, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2014/062286, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171720.9, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
FIELD OF THE INVENTION
The present invention belongs to the field of medical chemistry and relates to the compound of formula (I), a primary triclyclic amine, which inhibits the tPA-induced activation of the enzyme Erk 1/2 and is promising for, the treatment of neurodegenerative illnesses, such as,
BACKGROUND OF THE INVENTION
The present invention relates to novel tricyclic sulfonamide compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
BACKGROUND OF THE INVENTION
The present invention relates to novel tricyclic sulfonamide compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2015/079981, filed Dec. 16, 2015, which claims priority from European Patent Application No. 14198977.2, filed Dec. 18, 2014 and European Patent Application No. 15164704.7, filed Apr. 22,
BACKGROUND OF THE INVENTION
The present invention relates to novel biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to